Heat Biologics (HTBX) Tops Q3 EPS by 7c
- Goldman sends Dow to record high, techs lift S&P, Nasdaq
- Oil tops $55 for first time in 16 months as OPEC deal fuels buying
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
- Burberry rejects multiple takeover offers from Coach: Financial Times
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Heat Biologics (NASDAQ: HTBX) reported Q3 EPS of ($0.08), $0.07 better than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Heat Biologics (HTBX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades National Beverage (FIZZ) to Outperform
- Heat Biologics (HTBX) Files Amended Securities Prospectus Supplement
- G-III Apparel Group (GIII) Misses Q3 EPS by 4c, Offers Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!